Teva Pharmaceutical Industries Ltd.

Israel-based AION Labs, an AI-enabled drug discovery partnership between global pharma and tech companies, has launched ProPhet, a startup using artificial intelligence to locate small molecules for drug discovery. ProPhet was established following AION Labs' startup challenge focused on AI-powered drug discovery of new high-affinity small molecules. The aim is to address the market need to speed up, refine and enhance the early stages of drug discovery by focusing on proteins that are challenging because of finite information while substantially lowering the time and cost of identifying potential drug candidates for these targets. According to the company, ProPhet speaks to the biological and computational obstacles by using state of the art machine learning technologies, like diffusion models and LLMs to create optimized novel algorithms. "Proteins are influenced by their surroundings, which can cause them to adopt various possible conformational states," Tom Shani, CEO of ProPhet, said in a statement. "Our platform enables us to both evaluate these different states and screen vast small molecule libraries against them in a highly scalable manner. AION Labs has provided the perfect environment for our company to grow, with the opportunity to partner with the strongest players in the pharmaceutical industry to optimize our design process. This ensures we are well-aligned with the industry's priorities and needs." Mati Gill, CEO of AION Labs, noted that small molecules make up most of the developed drugs, making ProPhet's method particularly important via its broad applicability across a wide range of treatments. "Dr. Shani has formed the ideal team for this space, possessing the perfect combination of biological, chemistry and computational expertise. We are excited to support ProPhet with the necessary resources and connections to succeed," Gill said in a statement. THE LARGER TREND Founded in 2021, AION labs works with major pharma companies, including AstraZeneca, Merck, Pfizer, Israel Biotech Fund and Teva Pharmaceuticals, as well as tech company Amazon Web Services and German independent research institute Bio Med X. In March, AION Labs launched a startup, CombineAble.AI, designed to speed up the development of therapeutics by addressing challenges connected to antibody design. The company develops a platform that combines AI with computational methods for biomolecule simulations aimed at developing new biotherapeutics. In January, AION Labs launched a new startup, TenAces. The company utilizes AI, integrating biology and machine learning algorithms, to discover molecular glue therapies to improve targeted protein degradation. In 2023, AION launched its second startup, DenovAI. DenovAI is an AI-enabled computational biophysics platform that can discover potential antibodies directed toward specific epitopes (the part of an antigen molecule recognized by the immune system to which an antibody attaches itself). The platform designs antibodies from scratch, then suggests which candidates will most likely produce effective drugs. The company launched OMEC.AI in 2022, which aims to build an AI-enabled computational platform to help researchers assess the clinical trial readiness of a drug candidate, identify hidden safety liabilities and suggest experiments to close any identified gaps. PromiseBio is another AION Labs company that offers epiproteomic analysis for precision medicine with the aim to decipher biological insights into complex chronic conditions, including autoimmune diseases.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies London Healthcare Conference, November 19-20, 2024. Members of the management team will host one-on-one meetings on both days. Alvotech will be presenting at the conference on Tuesday, November 19, 2024 at 9:00-9:25 am GMT. An audio webcast of the conference presentation will also be available to investors and the general public and can be accessed in the Investors Section of Alvotech’s website under News and Events – Events and Presentations . After the event, a recording will also be available for 90 days. About Alvotech Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit Please visit our investor portal , and our website or follow us on social media on LinkedIn , Facebook , Instagram , X and YouTube . ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS Benedikt Stefansson, VP alvotech.ir@alvotech.com

Agomab’s lead candidate is being investigated as a treatment for patients with fibrostenosing Crohn’s disease (FSCD). Credit: Hananeko_Studio via Shutterstock. Agomab Therapeutics has secured $89m in Series D funding to support clinical trials of its fibrotic disease treatments, with some help from Sanofi . Belgium-based Agomab announced that Sanofi and Invus have joined as new investors in its latest funding round, following on from a $100m Series C round in October 2023, and a $114m Series B where Pfizer led an extension round. The funds will be used to advance the development of Agomab’s lead candidate AGMB-129, a treatment for patients with fibrostenosing Crohn’s disease (FSCD). The oral small molecule inhibitor of ALK5 (TGFβ1R) is currently being investigated in the Phase IIa STENOVA trial (NCT05843578). The company expects to share interim results from the 90-patient trial in early 2025. Positive data from the Phase I trial (NCT04933565) of AGMB-129 was reported in February 2023, where the candidate demonstrated high local exposure in the ileum, with no drug-related safety signals or dose-limiting toxicities. Patients with FSCD have strictures in the intestines caused by inflammation and scarring, for which there is no cure. The company also has an inhaled treatment for idiopathic pulmonary fibrosis (IPF), named AGMB-447, and a liver cirrhosis candidate AGMB-101. AGMB-447 is being investigated in a Phase I trial (NCT06181370) and Agomab plans to start clinical development of AGMB-101, which is “in the final stages of IND-enabling studies”. See Also: Dyno and Roche collaborate on neurological gene therapies Takeda and BMC partner to decarbonise US healthcare sector Sanofi continues to assert itself in the immunology space, signing deals with parties such as Recludix, Teva Pharmaceutical and IGM Biosciences . The company expanded its immunology pipeline further in June 2024, entering a $700m strategic partnership with Belharra Therapeutics to spur the development of small molecule therapies for immunological diseases. Sanofi and Regeneron’s immune-targeting biologic Dupixent (dupilumab) has been picking up label expansions since its 2017 US Food and Drug Administration (FDA) approval for atopic dermatitis. The drug earned $11.6bn last year, as per Regeneron’s financials, and is set to generate $23.6bn in 2030, according to GlobalData consensus forecasts. GlobalData is the parent company of Pharmaceutical Technology. In the announcement accompanying the funding, Agomab’s CEO Tim Knotnerus said: “We are thrilled to have Sanofi and Invus joining our investor syndicate. Their investment as well as the continued support from our existing shareholders is another validation of the trailblazing work our team is conducting in the fields of fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis.”